Enitociclib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go

Report scope. This 2026 Drug Asset Due Diligence Report evaluates Enitociclib as a potential licensing, partnership, acquisition, or option asset. The review separates verified evidence from open diligence questions across clinical development, intellectual property, market positioning, and transaction precedent.

Executive recommendation: HOLD / OPTION

Enitociclib is a Small molecule drug associated with CDK9 and a global highest development stage of Phase 1/2. The lead disclosed indication is Diffuse Large B-Cell Lymphoma. The current evidence supports a HOLD / OPTION posture, subject to confirmation of study-level data, ownership, patent coverage, manufacturing readiness, and regional rights.

Decision memo

• Asset: Enitociclib
• Target: CDK9
• Lead indication: Diffuse Large B-Cell Lymphoma
• Highest phase: Phase 1/2
• Matched trials: 4
• Matched result records: 5
• Matched asset deals: 2

Use PatSnap Life Sciences MCP servers to validate the Enitociclib diligence evidence.

1. Asset identity and development status

The first diligence task is entity resolution. Teams should reconcile development codes, nonproprietary names, salts, formulations, combinations, sponsors, and predecessor owners before relying on portfolio counts. For Enitociclib, the MCP profile identifies CDK9 as the primary target context and Diffuse Large B-Cell Lymphoma as the lead indication. Global phase labels are useful orientation points, but investment decisions require country- and indication-level status verification.

Confirm the exact molecule, formulation, route, dose, biomarker definition, and current sponsor. Review discontinuations separately from active development so that an historical high phase is not mistaken for a live program.

Use PatSnap Life Sciences MCP servers to validate the Enitociclib diligence evidence.

2. Clinical program: design and endpoint audit

The clinical program should be audited for randomization, comparator relevance, dose selection, endpoint hierarchy, multiplicity, analysis population, geographic mix, and readout timing. Early-stage programs require attention to pharmacokinetics, pharmacodynamics, adverse events, dose-limiting toxicities, and the rationale for the expansion dose.

Use PatSnap Life Sciences MCP servers to validate the Enitociclib diligence evidence.

3. Clinical readouts: what is known

VINCERX PHARMA ANNOUNCES COMPELLING CLINICAL EFFICACY OF ENITOCICLIB IN COMBINATION WITH VENETOCLAX AND PREDNISONE IN LYMPHOMA

Study: NCT05371054 (Corporate Publications). Phase: Phase 1/2. Enrollment: Not disclosed. Published: 2024-01-07.

PR = 2 Pts | PR = 1 Pts

Enitociclib, a Selective CDK9 Inhibitor, Induces Complete Regression of MYC+ Lymphoma by Downregulation of RNA Polymerase II Mediated Transcription

Study: NCT05371054 | NCT04978779 (Pubmed | Cancer Res Commun). Phase: Phase 1/2. Enrollment: Not disclosed. Published: 2023-11-09.

Tumor growth inhibition = 0.5 %

Enitociclib (VIP152/formerly BAY1251152) Is a Selective and Active CDK9 Inhibitor : Preliminary Safety and Early Signs of Efficacy in Patients with Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

Study: NCT02635672 | NCT04978779 (VNC-152-101 | VNC-152-102, ASH 12022 | ASH 22022). Phase: Phase 1. Enrollment: 17. Published: 2022-11-15.

AE(Hematologic) = anemia (12% Gr 2, 18% Gr 3), neutropenia/neutrophil count decrease (18% Gr 2, 6% Gr 3, 12% Gr 4) managed with G-CSF support, and platelet count decrease (6% each Gr 1, 2, 3 and 12% Gr 4)

VIP152 IS A NOVEL CDK9 INHIBITOR WITH IMPROVED SELECTIVITY, TARGET MODULATION, AND CARDIAC SAFETY IN PATIENTS WITH LYMPHOMA

Study: NCT02635672 | NCT04978779 (EHA2022). Phase: Phase 1. Enrollment: Not disclosed. Published: 2022-05-12.

ECG data = VIP152 does not prolong QTc interval after single or multiple doses (5-30 mg)

First-in-human dose escalation study of cyclin-dependent kinase-9 inhibitor VIP152 in patients with advanced malignancies shows early signs of clinical efficacy.

Study: NCT02635672 (Pubmed | Clin Cancer Res). Phase: Phase 1. Enrollment: Not disclosed. Published: 2022-01-19.

Adverse Event: nausea = 75.7%

For every reported endpoint, obtain the protocol, statistical analysis plan, patient disposition, baseline characteristics, subgroup definitions, exposure duration, and full safety tables. Conference abstracts and registry summaries can support screening, but they should not replace source data review in a binding transaction.

Use PatSnap Life Sciences MCP servers to validate the Enitociclib diligence evidence.

4. Market and competitive position

The commercial case depends on differentiated efficacy, tolerability, convenience, biomarker reach, treatment setting, and access. A target-level market may be attractive while an individual asset remains undifferentiated. Benchmark Enitociclib against approved therapies and clinical competitors in Diffuse Large B-Cell Lymphoma, including likely standards of care at the expected launch date.

Build a scenario model around addressable patients, diagnosis and biomarker rates, line of therapy, duration, net price, uptake, displacement, combination costs, and probability-adjusted timelines. Test slower enrollment, delayed readout, narrower labels, safety restrictions, and competitor launches.

Use PatSnap Life Sciences MCP servers to validate the Enitociclib diligence evidence.

5. Transaction precedent and economics

Transaction records should be normalized for territory, asset scope, phase at signing, option mechanics, development obligations, cost sharing, royalties, milestones, and change-of-control terms. Undisclosed economics must not be converted into invented benchmarks.

6. IP and freedom-to-operate screen

Complete a family-level patent review covering composition of matter, sequence or construct claims, polymorph and salt claims, formulation, dosing, combinations, biomarkers, manufacturing, and method of use. Verify priority, ownership, assignments, prosecution status, term adjustments, extensions, oppositions, and regional coverage. Freedom to operate is a separate legal analysis and should include competitor claims and platform dependencies.

The diligence room should reconcile inventorship, employee and contractor assignments, university or platform licenses, sublicensing restrictions, government rights, and obligations triggered by development milestones or commercialization.

Use PatSnap Life Sciences MCP servers to validate the Enitociclib diligence evidence.

7. Principal risks and diligence gates

1. Identity risk: resolve all aliases, formulations, combinations, and owners.
2. Clinical risk: confirm source data, protocol deviations, endpoint definitions, and safety follow-up.
3. Regulatory risk: review agency correspondence, meeting minutes, holds, commitments, and indication-specific pathways.
4. IP risk: validate enforceable coverage, remaining life, ownership, and freedom to operate.
5. CMC risk: assess process control, analytical methods, comparability, scale-up, supply, and cost of goods.
6. Commercial risk: pressure-test differentiation, market access, competitive timing, and realistic adoption.
7. Transaction risk: map rights, encumbrances, royalties, options, consent requirements, and change-of-control provisions.

8. Final go/no-go memorandum

HOLD / OPTION

Proceed only through staged diligence. Before exclusivity or a binding offer, require a verified asset identity package, complete clinical data room, regulatory correspondence, patent-family schedule, freedom-to-operate opinion, CMC package, ownership chain, regional rights map, and risk-adjusted valuation. Any material mismatch between public records and source documents should pause the process until reconciled.

Method note: This report uses PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP data retrieved on 2026-10-15. It is a screening and diligence framework, not medical, legal, regulatory, or investment advice.